Identificador persistente para citar o vincular este elemento:
http://hdl.handle.net/10553/127387
Campo DC | Valor | idioma |
---|---|---|
dc.contributor.author | Saro, C | en_US |
dc.contributor.author | Ceballos Santos, Daniel Sebastián | en_US |
dc.contributor.author | Muñoz, F | en_US |
dc.contributor.author | De la Coba, C | en_US |
dc.contributor.author | Aguilar, MD | en_US |
dc.contributor.author | Lázaro, P | en_US |
dc.contributor.author | Iglesias Flores, E | en_US |
dc.contributor.author | Barreiro de Acosta, M | en_US |
dc.contributor.author | Hernández Durán, MD | en_US |
dc.contributor.author | Barrio, J | en_US |
dc.contributor.author | Bode Riestra, Antonio | en_US |
dc.contributor.author | Salazar, LF | en_US |
dc.date.accessioned | 2023-10-25T10:41:13Z | - |
dc.date.available | 2023-10-25T10:41:13Z | - |
dc.date.issued | 2015 | en_US |
dc.identifier.issn | 1078-0998 | en_US |
dc.identifier.uri | http://hdl.handle.net/10553/127387 | - |
dc.description.abstract | Background: This study examines the resources utilization in patients with Crohn's disease (CD) during the year before (Y - 1) and after (Y + 1) starting treatment with adalimumab and the drug's efficiency. Methods: Observational, multicenter, prospective cohort study of patients with CD naive to biological drugs. The proportion of patients with CD Activity Index (CDAI) <150 was considered as the effectiveness variable. Costs considered were direct costs (DC) related to the use of health care resources, and indirect costs (IC) related to sick leave in Y - 1 and Y + 1. Adalimumab efficiency was estimated as the incremental cost/effectiveness ratio. A deterministic sensitivity analysis was performed building 3 scenarios: base case, the least favorable, and the most favorable case for adalimumab. Results: In the cohort of 126 patients (50.8% men; age 39.1 ± 13.8 yr), the proportion of patients in remission increased from 34.1% by the end of Y - 1 to 83.3% by the end of Y + 1. Although the DC increase by the use of adalimumab, the use of doctor visits, emergency room visits, laboratory tests, diagnostic examinations, and nonbiological drug treatment were lower (P < 0.05) in Y + 1 than Y - 1. In the base case scenario, considering only DC, the incremental cost/effectiveness ratio was €31,308 and including IC, it was €28,936. In patients with CDAI > 150 at the onset, incremental cost/effectiveness ratio was €20,119 and €18,223, considering DC alone or included IC, respectively. Conclusions: In patients with CD, adalimumab increases pharmacological costs at the expense of biological therapy but reduces the cost of other drugs, the use of health care resources, and IC. Adalimumab efficiency is 30% greater in patients with CDAI > 150. | en_US |
dc.language | eng | en_US |
dc.relation.ispartof | Inflammatory Bowel Diseases | en_US |
dc.source | Inflammatory Bowel Diseases, [ISNN 1078-0998], v. 21 (7), p. 1631-1640, (July 2015) | en_US |
dc.subject | 32 Ciencias médicas | en_US |
dc.subject.other | Adalimumab | en_US |
dc.subject.other | Crohn's disease | en_US |
dc.subject.other | IBD | en_US |
dc.subject.other | Resources utilization | en_US |
dc.title | Resources utilization and costs the yearbBefore and after starting treatment with Adalimumab in Crohn's Disease patients | en_US |
dc.type | Article | en_US |
dc.identifier.doi | 10.1097/MIB.0000000000000413 | en_US |
dc.identifier.pmid | 25961910 | - |
dc.identifier.scopus | 2-s2.0-84932120842 | - |
dc.identifier.isi | WOS:000356602200018 | - |
dc.contributor.orcid | #NODATA# | - |
dc.contributor.orcid | #NODATA# | - |
dc.contributor.orcid | #NODATA# | - |
dc.contributor.orcid | #NODATA# | - |
dc.contributor.orcid | #NODATA# | - |
dc.contributor.orcid | #NODATA# | - |
dc.contributor.orcid | #NODATA# | - |
dc.contributor.orcid | #NODATA# | - |
dc.contributor.orcid | #NODATA# | - |
dc.contributor.orcid | #NODATA# | - |
dc.contributor.orcid | #NODATA# | - |
dc.contributor.orcid | #NODATA# | - |
dc.identifier.issue | 7 | - |
dc.investigacion | Ciencias de la Salud | en_US |
dc.utils.revision | Sí | en_US |
dc.identifier.ulpgc | Sí | en_US |
dc.contributor.buulpgc | BU-MED | en_US |
dc.description.sjr | 2,348 | |
dc.description.jcr | 4,358 | |
dc.description.sjrq | Q1 | |
dc.description.jcrq | Q1 | |
dc.description.scie | SCIE | |
item.fulltext | Sin texto completo | - |
item.grantfulltext | none | - |
crisitem.author.dept | Departamento de Ciencias Médicas y Quirúrgicas | - |
crisitem.author.orcid | 0000-0003-2384-4524 | - |
crisitem.author.fullName | Ceballos Santos, Daniel Sebastián | - |
crisitem.author.fullName | Bode Riestra,Antonio | - |
Colección: | Artículos |
Citas SCOPUSTM
7
actualizado el 25-ago-2024
Citas de WEB OF SCIENCETM
Citations
6
actualizado el 25-ago-2024
Visitas
71
actualizado el 11-may-2024
Google ScholarTM
Verifica
Altmetric
Comparte
Exporta metadatos
Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.